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There is substantial need for effective treatments in 
pediatric AD (1). Mild topical corticosteroids and basic 
emollients are used as first-line. In non-responsive cases 
and frequent relapses, topical calcineurin inhibitors 
are recommended (2). For children over 2 years of age 
0,03% tacrolimus ointment and 1% pimecrolimus cream 
have been approved (3). 0,1% tacrolimus ointment has 
been used off-label in pediatric AD (4), but there is still 
limited data regarding long-term treatment in children 
under 2 years of age (5). We analysed the use and safety 
data of topical tacrolimus in small children with AD and 
compared the usage with topical corticosteroids. 
MATERIALS, METHODS AND RESULTS
Interim analysis of a three-year follow-up study (4) was conduc-
ted, comparing 2 treatment modalities; tacrolimus ointment (both 
0.03% and 0.1%) and topical corticosteroids (mild and mid-poten-
cy), in a cohort of 1 to 3 year old children. This was a randomized 
non-blinded follow up study with a one week wash-out period. 
A total of 152 children with moderate to severe AD (Rajka 
and Langeland Eczema Severity Score) (4) were randomized 
for topical corticosteroids (hydrocortisone 1% and if needed 
hydrocortisone-17-butyrate cream) or topical tacrolimus (0.03% 
and if needed 0.1% ointment). There was a drop out of 15 patients 
during the first year due to nonadherence. Patients were advised 
to use topical corticosteroids twice per day for courses of 3-5 
days or topical tacrolimus twice daily until the skin has cleared 
and thereafter twice per week if needed. Clinical assessment 
(including use of topical treatment) and assessment of severity 
were performed after the first week, at months 1, 3, 6, 9 and 12 
and thereafter every 6 months. 
At baseline, blood eosinophil count, total serum IgE, specific 
IgE antibodies (aeroallergens and food allergens) and skin prick 
tests were measured to investigate if early signs of atopy predict 
response to treatments. The cohort is characterized in detail in a 
former publication (4).
Fifty-one patients (85.0%) in the corticosteroid group (n = 60) 
and 50 (78.1%) in the tacrolimus group (n =  64) needed to switch 
to a more potent treatment. There were no significant differences 
between groups (p = 0.325, χ2-test; Fig. 1). 
Disease severity and high Eczema Area and Severity Index 
(EASI) score predicted the need for more potent treatment 
(p = 0.009, Mann–Whitney U test). Switch to more potent treatment 
was due to poor treatment response in localized body sites (limbs, 
trunk, lichenified areas) or to frequent relapses. The switch to a 
more potent treatment was mostly needed on the extremities. If 
the patients needed a more potent treatment they usually needed it 
during the first follow-up year. Here, the treatment was switched 
to either hydrocortisone-17-butyrate cream (corticosteroid group) 
or tacrolimus 0,1% ointment (tacrolimus group).  Characteristics 
of the treatment groups are shown in Table SI1. Comparisons of 
the treatment groups are shown in Table SII1 and Fig. 2.
Signs of atopy did not predict the need for a more potent tre-
atment (p = 0.779, Fisher’s exact test). No sex differences were 
observed. Only the clinical disease severity (EASI) correlated 
with the need for a more potent treatment, i.e. physician observed 
non-responsiveness or frequent relapses after withdrawal of milder 
topical treatment.
Tacrolimus blood concentrations were measured in the tacro-
limus group (0.03% and 0.1%) at 1-week and 1-year visits. Five 
patients at week 1 had a tacrolimus concentration slightly above 
normal, but the values normalized (< 1.5 µg/l) in control samples 
taken the following week (data shown previously) (4). 
DISCUSSION 
In our experience many small infants and toddlers with 
moderate to severe AD need an off-label use of more po-
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Fig. 1. Comparison of treatment 
groups. (a) Switch to more potent 
treatment. (b) Group characteristics 
at baseline; T1=0.03% tacrolimus 
ointment only; T2=0.03% and 
0.1% tacrolimus ointment; C1: 





































































tent topical tacrolimus (0.1% ointment) or corticosteroid 
treatment (mid potency corticosteroids) to control the 
disease (6). Milder treatment may often not be sufficient 
with a risk of disease chronicity (7, 8).
Pediatric patients with moderate or severe AD may be 
undertreated due to fear of adverse effects (9, 10). Both 
hydrocortisone 1% cream and 0.03% tacrolimus ointment 
were in our cohort insufficient to control more severe AD. 
In addition, prior to study inclusion, many of the patients 
were insufficiently treated, often mostly with emollients. 
Compliance issues and parental collaboration are re-
cognized challenges in pediatric AD, which affects the 
quality of life of patients and their families (11, 12). In 
severe AD, the incidence of lymphoma might be increased 
in later life (13).
There have been concerns associated with the use of 
topical tacrolimus and corticosteroids in infants (14). 
How ever, intermittent topical mid-potency corticosteroids 
do not pose a high risk for adverse effects small infants and 
toddlers (15). Based on the official approval and treatment 
guidelines 0.1% tacrolimus ointment is not recommended 
for patients under the age 15 years (2). 
In our patient cohort, long-term treatment with tacroli-
mus 0.1% ointment was safe and effective in pediatric AD 
(4). Systemic exposure to tacrolimus was not significant. 
The topical treatment was well tolerated, with side effects 
like pruritus and burning sensation mostly disappearing 
after continuous use. Many patients required a switch to 
a more potent topical treatment, mostly during the first 
year of follow up. We encourage this in cases of poor 
response to first line treatments, frequent disease flares 
and lichenified lesions on the extremities (7, 14). 
In conclusion, our cohort of small infants and toddlers 
with moderate and severe AD seemed to be undertreated 
and there was a substantial need the switch to a more 
potent treatment (4, 6). Our observations do not provide 
direct evidence that pediatric atopic dermatitis is under-
treated and more studies are needed to confirm our ob-
servations representing the situation in Finland. There 
might also be an increased risk of disease chronicity and 
other co-morbidities (11, 12). Our study shows that small 
infants with treatment refractory atopic dermatitis profit 
from the switch to a more potent topical treatment, i.e. 
mid-potency corticosteroids or 0.1% tacrolimus. 
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